Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE)

Journal of Clinical Oncology

Volumn 33, Issue 35, 2015, Pages 4194-4201

  Eberhardt, Wilfried Ernst Erich ^a   Pöttgen, Christoph ^a   Gauler, Thomas Christoph ^a   Friedel, Godehard ^c   Veit, Stefanie ^c   Heinrich, Vanessa ^d   Welter, Stefan ^b   Budach, Wilfried ^d   Spengler, Werner ^d   Kimmich, Martin ^c   Fischer, Berthold ^e   Schmidberger, Heinz ^e   De Ruysscher, Dirk ^g   Belka, Claus ^f   Cordes, Sebastian ^a   Hepp, Rodrigo ^a   Lütke Brintrup, Diana ^a   Lehmann, Nils ^a   Schuler, Martin ^a   Jöckel, Karl Heinz ^a   Stamatis, Georgios ^b   Stuschke, Martin ^a   more..

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b RUHRLANDKLINIK   (Germany)

^c Klinik Schillerhohe   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g MAASTRO CLINIC   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NAVELBINE; PACLITAXEL; ANTINEOPLASTIC AGENT; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; BILOBECTOMY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; EMPYEMA; ESOPHAGITIS; FATIGUE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LOBECTOMY; LUNG DISEASE; LUNG RESECTION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PAIN; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEGMENTECTOMY; STOMATITIS; THORACOTOMY; THROMBOCYTOPENIA; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RADIATION DOSE FRACTIONATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PNEUMONECTOMY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 84957453635     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.6812     Document Type: Article

References (31)

1. Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65:87-108, 2015
2. Goldstraw P, Crowley J, Chansky K, et al: The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:706-714, 2007
3. Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al: Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi89-vi98, 2013 (suppl 6)
4. Curran WJ Jr, Paulus R, Langer CJ, et al: Sequential vs. concurrent chemoradiation for stage III non-small-cell lung cancer: Randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452-1460, 2011
5. Aupérin A, Le Péchoux C, Rolland E, et al: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-2190
6. Van Meerbeeck JP, Kramer GW, Van Schil PE, et al: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99:442-450, 2007
7. Bradley J, Masters GA, Hu C, et al: PL03.05 An intergroup randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) chemoradiotherapy +/- cetuximab for stage III non-small cell lung cancer (NSCLC): Results on cetuximab from RTOG 0617. J Thorac Oncol 8:S3, 2013 (suppl 2)
8. Mauguen A, Pignon JP, Burdett S, et al: Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: A re-analysis of meta-analyses of individual patients' data. Lancet Oncol 14:619-626, 2013
9. Albain KS, Swann RS, Rusch VW, et al: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet 374:379-386, 2009
10. Eberhardt WE, Gauler TC, LePechoux C, et al: 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC): A multicenter phase-II trial (CISTAXOL). Lung Cancer 82:83-89, 2013
11. Eberhardt W, Wilke H, Stamatis G, et al: Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: Mature results of a phase II trial. J Clin Oncol 16:622-634, 1998
12. Pöttgen C, Eberhardt W, Bildat S, et al: Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): A pilot phase I/II trial. Ann Oncol 13:403-411, 2002
13. Pöttgen C, Eberhardt WE, Gauler T, et al: Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer: Safety and toxicity results within a prospective trial. Int J Radiat Oncol Biol Phys 76:809-815, 2010
14. Mountain CF: Revisions in the International System for Lung Cancer. Chest 111:1710-1717, 1997
15. Zelen M: The randomization and stratification of subjects to clinical trials. J Chronic Dis 27:365-375, 1974
16. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
17. Schoenfeld DA, Hui Z, Finkelstein DM: Bayesian design using adult data to augment pediatric trials. Clin Trials 6:297-304, 2009
18. Lüchtenborg M, Riaz SP, Coupland VH, et al: High procedure volume is strongly associated with improved survival after lung cancer surgery. J Clin Oncol 31:3141-3146, 2013
19. Albain KS, Crowley JJ, Turrisi AT III, et al: Concurrent cisplatin etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20:3454-3460, 2002
20. Stupp R, Mayer M, Kann R, et al: Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: A multicentre phase II trial. Lancet Oncol 10:785-793, 2009
21. Friedel G, Budach W, Dippon J, et al: Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: A single-center study. J Clin Oncol 28:942-948, 2010
22. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
23. Zatloukal P, Petruzelka L, Zemanova M, et al: Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small-cell lung cancer: A randomized study. Lung Cancer 46:87-98, 2004
24. van Baardwijk A, Reymen B, Wanders S, et al: Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small-cell lung cancer. Eur J Cancer 2012;48:2339-2346
25. Weder W, Collaud S, Eberhardt WE, et al: Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg 139:1424-1430, 2010
26. Pless M, Stupp R, Ris HB: Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small-cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Res (SAKK trial 16/00). J Clin Oncol 31:2013 (Suppl; Abstr 7503)
27. Pless M, Stupp R, Ris H, et al: Final results of the SAKK 16/00 Trial: A randomized phase III trial comparing neoadjuvant chemoradiation to chemotherapy alone in stage IIIA/N2 non-small-cell lung cancer. Ann Oncol 25:1v417, 2014 (suppl 4)
28. Betticher DC, Schmitz SH, Tötsch M, et al: Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: A multicenter phase II trial. J Clin Oncol 21:1752-1759, 2003
29. Pöttgen C, Eberhardt W, Graupner B, et al: Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small-cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation. Eur J Cancer 49:2107-2115, 2013
30. Vokes EE, Herndon JE II, Kelley MJ, et al: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 725:1698-1704, 2007
31. Pignon JP, Tribodet H, Scagliotti GV, et al: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552-3559, 2008